Pfizer and BioNTech announced Tuesday that they have formally submitted an application to the Food and Drug Agency (FDA) to authorize the emergency use of a third dose of its Covid-19 vaccine for people over 18 years old.
The companies reported in late October that clinical trials conducted on 100,000 people found the third dose of their vaccine to be 95.6% effective against symptomatic infection.
The FDA It had already granted emergency use authorization in September for a third dose of the vaccine from the two companies for people over 65 years of age, as well as for people at high risk of developing a severe form of Covid-19.
Pfizer’s initial proposal for approval of the third dose to all persons 16 years of age and older, supported by the administration of President Joe Biden, was rejected by the FDA at that time.
Several countries have approved vaccines for reinforcement against Covid-19 to increase immunity, since some studies revealed that the protection of the inoculated decreases after several months.
The European Medicines Agency (EMA) approved the booster dose for over 18s in early October, allowing national regulators to decide which groups should be chosen first.
kg
Reference-www.eleconomista.com.mx